Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 2Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 7244Neoplasms 4539Prostatic Neoplasms 3489Colorectal Neoplasms 2940Carcinoma, Non-Small-Cell Lung 2831Lung Neoplasms 2547Leukemia, Myeloid, Acute 1982Pancreatic Neoplasms 1874Multiple Myeloma 1811Carcinoma, Hepatocellular 1733Neoplasm Metastasis 1585Stomach Neoplasms 1502Lymphoma 1457Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Head and Neck Neoplasms 1435Brain Neoplasms 1373Melanoma 1348Ovarian Neoplasms 1342Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1138Uterine Cervical Neoplasms 1096Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 936Lymphoma, Large B-Cell, Diffuse 932Squamous Cell Carcinoma of Head and Neck 921

Interventions

sotorasib 1niraparib 1Panitumumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × Efficacy × Clear all
NCT06237205 2024-02-01

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Korea University Anam Hospital

Phase 2 Not yet recruiting
33 enrolled

Efficacy

NCT05993455 2023-08-15

A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab

Korea University Anam Hospital

Phase 2 Unknown
24 enrolled

Efficacy

NCT05325684 2022-04-13

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

The Affiliated Hospital of Qingdao University

Phase 1/2 Unknown
30 enrolled

Efficacy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡